FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1506738181> ?p ?o ?g. }

• W1506738181 endingPage "756" @default.
• W1506738181 startingPage "746" @default.
• W1506738181 abstract "We investigated the effects of nilotinib plus multiagent chemotherapy, followed by consolidation/maintenance or allogeneic hematopoietic cell transplantation (allo-HCT) for adult patients with newly diagnosed Philadelphia-positive (Ph-pos) acute lymphoblastic leukemia (ALL). Study subjects received induction treatment that comprised concurrent vincristine, daunorubicin, prednisolone, and nilotinib. After achieving complete hematologic remission (HCR), subjects received either 5 courses of consolidation, followed by 2-year maintenance with nilotinib, or allo-HCT. Minimal residual disease (MRD) was assessed at HCR, and every 3 months thereafter. The molecular responses (MRs) were defined as MR3 for BCR-ABL1/G6PDH ratios ≤10(-3) and MR5 for ratios <10(-5). Ninety evaluable subjects, ages 17 to 71 years, were enrolled in 17 centers. The HCR rate was 91%; 57 subjects received allo-HCT. The cumulative MR5 rate was 94%; the 2-year hematologic relapse-free survival (HRFS) rate was 72% for 82 subjects that achieved HCR, and the 2-year overall survival rate was 72%. Subjects that failed to achieve MR3 or MR5 were 9.1 times (P = .004) or 6.3 times (P = .001) more prone to hematologic relapse, respectively, than those that achieved MR3 or MR5. MRD statuses just before allo-HCT and at 3 months after allo-HCT were predictive of 2-year HRFS. Adverse events occurred mainly during induction, and most were reversible with dose reduction or transient interruption of nilotinib. The combination of nilotinib with high-dose cytotoxic drugs was feasible, and it effectively achieved high cumulative complete molecular remission and HRFS rates. The MRD status at early postremission time was predictive of the HRFS. This trial was registered at www.clinicaltrials.gov as #NCT00844298." @default.
• W1506738181 created "2016-06-24" @default.
• W1506738181 creator A5001916257 @default.
• W1506738181 creator A5002662971 @default.
• W1506738181 creator A5006422911 @default.
• W1506738181 creator A5011991294 @default.
• W1506738181 creator A5012675709 @default.
• W1506738181 creator A5015112169 @default.
• W1506738181 creator A5015908436 @default.
• W1506738181 creator A5019303498 @default.
• W1506738181 creator A5022259689 @default.
• W1506738181 creator A5024828401 @default.
• W1506738181 creator A5027919726 @default.
• W1506738181 creator A5031057863 @default.
• W1506738181 creator A5032838775 @default.
• W1506738181 creator A5036166097 @default.
• W1506738181 creator A5036888293 @default.
• W1506738181 creator A5040824212 @default.
• W1506738181 creator A5041987846 @default.
• W1506738181 creator A5044268319 @default.
• W1506738181 creator A5044342301 @default.
• W1506738181 creator A5044444009 @default.
• W1506738181 creator A5045264210 @default.
• W1506738181 creator A5048253912 @default.
• W1506738181 creator A5049891346 @default.
• W1506738181 creator A5057344958 @default.
• W1506738181 creator A5057787860 @default.
• W1506738181 creator A5058915727 @default.
• W1506738181 creator A5059730285 @default.
• W1506738181 creator A5060580143 @default.
• W1506738181 creator A5072574087 @default.
• W1506738181 creator A5073296574 @default.
• W1506738181 creator A5076088179 @default.
• W1506738181 creator A5076115706 @default.
• W1506738181 creator A5077318648 @default.
• W1506738181 creator A5081839494 @default.
• W1506738181 creator A5081967119 @default.
• W1506738181 creator A5082389619 @default.
• W1506738181 creator A5085596906 @default.
• W1506738181 creator A5086479486 @default.
• W1506738181 creator A5090760076 @default.
• W1506738181 date "2015-08-06" @default.
• W1506738181 modified "2023-10-18" @default.
• W1506738181 title "Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia" @default.
• W1506738181 cites W1510801288 @default.
• W1506738181 cites W1993808217 @default.
• W1506738181 cites W2000116184 @default.
• W1506738181 cites W2007030607 @default.
• W1506738181 cites W2030840471 @default.
• W1506738181 cites W2033862877 @default.
• W1506738181 cites W2036724262 @default.
• W1506738181 cites W2041353685 @default.
• W1506738181 cites W2050152294 @default.
• W1506738181 cites W2061440903 @default.
• W1506738181 cites W2065514651 @default.
• W1506738181 cites W2065851457 @default.
• W1506738181 cites W2073282372 @default.
• W1506738181 cites W2076668534 @default.
• W1506738181 cites W2080380323 @default.
• W1506738181 cites W2097799776 @default.
• W1506738181 cites W2099616647 @default.
• W1506738181 cites W2102929198 @default.
• W1506738181 cites W2105098746 @default.
• W1506738181 cites W2109487699 @default.
• W1506738181 cites W2120470347 @default.
• W1506738181 cites W2124174337 @default.
• W1506738181 cites W2125233997 @default.
• W1506738181 cites W2134566943 @default.
• W1506738181 cites W2135492799 @default.
• W1506738181 cites W2136161953 @default.
• W1506738181 cites W2139499066 @default.
• W1506738181 cites W2143939343 @default.
• W1506738181 cites W2148854558 @default.
• W1506738181 cites W2160248511 @default.
• W1506738181 cites W2171223909 @default.
• W1506738181 doi "https://doi.org/10.1182/blood-2015-03-636548" @default.
• W1506738181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26065651" @default.
• W1506738181 hasPublicationYear "2015" @default.
• W1506738181 type Work @default.
• W1506738181 sameAs 1506738181 @default.
• W1506738181 citedByCount "152" @default.
• W1506738181 countsByYear W15067381812015 @default.
• W1506738181 countsByYear W15067381812016 @default.
• W1506738181 countsByYear W15067381812017 @default.
• W1506738181 countsByYear W15067381812018 @default.
• W1506738181 countsByYear W15067381812019 @default.
• W1506738181 countsByYear W15067381812020 @default.
• W1506738181 countsByYear W15067381812021 @default.
• W1506738181 countsByYear W15067381812022 @default.
• W1506738181 countsByYear W15067381812023 @default.
• W1506738181 crossrefType "journal-article" @default.
• W1506738181 hasAuthorship W1506738181A5001916257 @default.
• W1506738181 hasAuthorship W1506738181A5002662971 @default.
• W1506738181 hasAuthorship W1506738181A5006422911 @default.
• W1506738181 hasAuthorship W1506738181A5011991294 @default.
• W1506738181 hasAuthorship W1506738181A5012675709 @default.
• W1506738181 hasAuthorship W1506738181A5015112169 @default.
• W1506738181 hasAuthorship W1506738181A5015908436 @default.

• next